Fiche publication
Date publication
mars 2026
Journal
Bulletin du cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DEBIEUVRE Didier
Tous les auteurs :
Corre R, Léna H, Eberlin A, Spampinato A, Guimard V, Dousa S, Debieuvre D
Lien Pubmed
Résumé
Immunotherapy has revolutionized the management of metastatic non-small cell lung cancer (NSCLC) without targetable alterations. Its use depends on histology, tumor PD-L1 expression, Performance Status (PS) score and patient age. The objective is to describe real-life therapeutic attitudes in France in 2020 and to analyze the adequacy with the professional standards applicable. The KBP-2020 study is a prospective observational study, including patients diagnosed de novo with primary lung cancer in 2020, followed in France in the participating non-university hospitals. Retrospective data analysis provides information on the first-line distribution of systemic treatments (immunotherapy, chemotherapy or the combination of both) in patients with stage IV NSCLC (542 squamous and 2082 non-squamous) without ALK rearrangement/alteration or EGFR mutations and PS score≤2. Immunotherapy alone or combined with chemotherapy is prescribed according to tumor PD-L1 expression: in case of PD-L1≥50%, in 85.2% of non-squamous and 86.6% of squamous patients, in case of PD-L1 [1-49%], in 61.7% of non-squamous and 45% of squamous patients and in case of PD-L1<1%, immunotherapy alone or combined with chemotherapy is prescribed in 56.48% of non-squamous and 30.86% of squamous patients. The use of immunotherapy in real life in 2020 in France shows an apparent gap with national guidelines that is more marked in cases of squamous cell NSCLC or with PD-L1 expression<50% with less exposure of patients to the immunotherapy-chemotherapy combination compared to current recommendations. This gap could be partly explained by the progressive reimbursement schedule of pembrolizumab and by other factors not documented in KBP-2020-CPHG.
Mots clés
Adherence, Cancer bronchique non à petites cellules métastatiques, Guideline, Immunotherapy, Immunothérapie, Lung cancer, Non-small cell lung cancer, Real-life, Recommandations, Vraie vie
Référence
Bull Cancer. 2026 03 30;:
